These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 30989645)
1. Enantiospecific Pharmacogenomics of Fluvastatin. Hirvensalo P; Tornio A; Neuvonen M; Kiander W; Kidron H; Paile-Hyvärinen M; Tapaninen T; Backman JT; Niemi M Clin Pharmacol Ther; 2019 Sep; 106(3):668-680. PubMed ID: 30989645 [TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229 [TBL] [Abstract][Full Text] [Related]
3. Associations between Zhang ZH; Yue Sun LC; Gu HY; Jiang C; Yi ZM Pharmacogenomics; 2023 Jun; 24(8):475-484. PubMed ID: 37318060 [No Abstract] [Full Text] [Related]
4. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Niemi M; Pasanen MK; Neuvonen PJ Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053 [TBL] [Abstract][Full Text] [Related]
5. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis. Xiang Q; Zhang X; Ma L; Hu K; Zhang Z; Mu G; Xie Q; Chen S; Cui Y Pharmacogenet Genomics; 2018 Dec; 28(12):261-267. PubMed ID: 30363031 [TBL] [Abstract][Full Text] [Related]
6. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers. Zhou Q; Ruan ZR; Yuan H; Zeng S Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809 [TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe. Caris JA; Benzi JRL; de Souza FFL; de Oliveira RDR; Donadi EA; Lanchote VL Eur J Pharm Sci; 2020 Apr; 146():105264. PubMed ID: 32058056 [TBL] [Abstract][Full Text] [Related]
9. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025 [TBL] [Abstract][Full Text] [Related]
10. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies. Lanchote VL; Rocha A; de Albuquerque FU; Coelho EB; Bonato PS J Chromatogr B Biomed Sci Appl; 2001 Dec; 765(1):81-8. PubMed ID: 11817313 [TBL] [Abstract][Full Text] [Related]
11. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers. Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210 [TBL] [Abstract][Full Text] [Related]
12. Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers. Boralli VB; Coelho EB; Sampaio SA; Marques MP; Lanchote VL J Clin Pharmacol; 2009 Feb; 49(2):205-11. PubMed ID: 19033449 [TBL] [Abstract][Full Text] [Related]
13. Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Kim MJ; Nafziger AN; Kashuba AD; Kirchheiner J; Bauer S; Gaedigk A; Bertino JS Eur J Clin Pharmacol; 2006 Jun; 62(6):431-6. PubMed ID: 16758259 [TBL] [Abstract][Full Text] [Related]
14. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Niemi M; Schaeffeler E; Lang T; Fromm MF; Neuvonen M; Kyrklund C; Backman JT; Kerb R; Schwab M; Neuvonen PJ; Eichelbaum M; Kivistö KT Pharmacogenetics; 2004 Jul; 14(7):429-40. PubMed ID: 15226675 [TBL] [Abstract][Full Text] [Related]
15. Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus. Naushad SM; Hussain T; Alrokayan SA; Kutala VK Pharmacol Rep; 2022 Oct; 74(5):1083-1091. PubMed ID: 35932448 [TBL] [Abstract][Full Text] [Related]
16. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants. Mukai Y; Narita M; Akiyama E; Ohashi K; Horiuchi Y; Kato Y; Toda T; Rane A; Inotsume N Biol Pharm Bull; 2017; 40(7):1078-1085. PubMed ID: 28674251 [TBL] [Abstract][Full Text] [Related]
17. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka. Ranasinghe P; Sirisena N; Ariadurai JN; Vishnukanthan T; Thilakarathne S; Anandagoda G; Dissanayake VH Pharmacogenomics; 2023 Oct; 24(15):809-819. PubMed ID: 37877238 [No Abstract] [Full Text] [Related]
19. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935 [TBL] [Abstract][Full Text] [Related]